Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Código da empresaITRM
Nome da EmpresaIterum Therapeutics PLC
Data de listagemMay 25, 2018
CEOFishman (Corey N)
Número de funcionários9
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 25
Endereço3 Dublin Landings
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD01 C4E0
Telefone35319038354
Sitehttps://www.iterumtx.com/
Código da empresaITRM
Data de listagemMay 25, 2018
CEOFishman (Corey N)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados